The novel coronavirus that emerged in 2019, like SARS outbreak of 2003, utilizes the ACE2 pathway as a means of cellular infection within the respiratory tract, among other organ systems throughout the body [1–3]. COVID-19 utilizes a spike protein that mediates viral entry into the host cell with ACE2 as the host receptor [4]. The potential magnitude that COVID-19 has as a global pandemic has garnered unprecedented attention within and outside of the scientific community. While the long-term goals for treatment of COVID-19 include the development of a vaccine that can attenuate the effects of this coronavirus, along with the potential testing and utilization of antivirals that may be effective, there is evidence that the ACE2 pathway can be modulated with existing medications, particularly those along the renin–angiotensin–aldosterone (RAAS) pathway [5,6]. Care must be taken, however, because evidence from both human and animal models suggest differences in the importance of ACE2 (and the product of ACE2, Ang(1–7) on the susceptibility to the infection and the cardiopulmonary response to the infection may be opposite. Specifically, it is possible that low ACE2 levels may be associated with relatively low infection rates [1]. However, there is abundant evidence in models of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) that lower ACE2 and Ang(1–7) levels are associated with poorer prognosis [3,7,8].

The early data on COVID-19 demonstrate that there is extreme heterogeneity in the severity of symptoms with transmission and infection. Some individuals have demonstrated transmission with no to mild symptoms, some have moderate symptoms that resolve, and others have severe symptoms that result in respiratory failure and, in extreme cases, death. These early data have demonstrated that younger individuals have no to relatively mild symptoms, whereas older individuals, men and individuals with hypertension and diabetes have demonstrated more severe symptoms, on average [9–11]. Once infected, the common causes of severe morbidity and mortality include ARDS and cardiac dysfunction [10]. These points are extremely important in that low ACE2 levels may be important in minimizing risk of infection with transmission (young animals, including humans, demonstrate low ACE2 levels [particularly before puberty], male animals have demonstrated higher ACE2 levels, and both hypertension and diabetes are associated with high ACE2 levels) [12]. However, after infection with coronavirus,
ACE2 and Ang(1–7) seem to have a protective effect on the pulmonary (reducing the severity of respiratory distress, pulmonary fibrosis, vascular leakage and pulmonary edema) and cardiac (reduction of cardiac injury, fibrosis, inhibition of cardiac hypertrophy and a reduction in the time of development of heart failure from cardiac hypertrophy in animal models) systems [3,7,9,13]. Using the early available data from COVID-19, that demonstrates comorbidities associated with high ACE2 levels are more likely to be infected, one can hypothesize that there are potential genetic variants that also influence the response to infection, given that common variants of renin, angiotensinogen, ACE and the Ang-II receptor have been shown to influence the function of the RAAS [14–18]. More recent data has also identified variants of ACE2 that have important differences in minor allele frequency between populations, but the mechanistic importance of these has yet to be clearly defined [19]. Therefore, it is possible, given the known heterogenous response of COVID-19, along with the importance of ACE2 for infection, that variants along the RAAS pathway may be a reason for differential infection symptoms and infection severity.

Given the unique paradigm of how ACE2 influences infection transmission and then the cardiac and pulmonary response to the infection, it is possible that there are differences in the desired ACE2 and Ang(1–7) levels for minimization of the infection and, then, the attenuation of the cardiopulmonary effects of the infection once infection has occurred. Interestingly, common hypertension medication modulation, including use of renin inhibitors, ACE inhibitors, and Ang-II receptor blockers (ARBs) may play a role in modulation of ACE2, based on previous studies [20,21]. These same medications have been shown to have a differential blood pressure lowering response based on common genetic variants of the RAAS [22,23]. This potential to modulate the infection, and complications from the infection, is important because it would be ideal to minimize these two while more sweeping and dramatic treatments are being developed. It is also possible that ACE2 modulation in response to RAAS medication adjustments may differ according to known functional genetic variants within the RAAS that have been previously shown to impact this pathway.

RAAS pathway & ACE2

There is evidence that the affinity of coronaviruses for ACE2 is important for viral infection [24,25]. ACE2 is a relatively newly discovered enzyme in the RAAS pathway. ACE2 is a homolog of the ACE but appears to be counteractive in nature to the function and activities of ACE and the product of ACE, Ang-II [5]. Within the RAAS pathway, renin cleaves angiotensinogen resulting in Ang-I. ACE then converts Ang-I to Ang-II, which is a primary drug target for patients with hypertension. Ang-II primarily binds to two types of receptors, the AT1 and AT2 receptors. ACE2 hydrolyzes Ang-I to make Ang(1–9) and hydrolyzes Ang-II to make Ang(1–7) that then binds to a GPCR MAS [6,26]. ACE, ACE2, Ang-II and AT1 receptor levels are high in the respiratory tract and lung, which seems to be the primary site of complications from the corona-type viruses [6]. It is thought that ACE2 activity may counteract the hypertensive effects of Ang-II in patients with high blood pressure, particularly early in hypertension, meaning that hypertension may increase endogenous ACE2 levels [5,6,27]. In addition to the lungs, ACE2 is expressed in the kidneys, nasal epithelium, vasculature, gastrointestinal system and pneumocytes [1,28]. Functional variants of renin, angiotensinogen, ACE and the AT1 receptor have been studied in detail and common variants have been shown to alter plasma levels, activity and the response to pharmacotherapy [22,23]. More recently, several common and functional genotypes of ACE2 have been described, one of these seems particularly impactful on modulation of ACE2 levels [19,29,30]. Therefore, while it is likely that a portion of the differences in COVID-19 infection rates and severity are influenced by environment or traditional demographic variables known to influence ACE2 levels, the known heterogeneity of this infection may also have genetic associations.

Evidence that ACE2 may be associated with COVID-19 infection

The early data from patients who have higher rates of infection and who have had more severe COVID-19 suggest that there are two primary common comorbidities: hypertension and diabetes [10]. In recent trials on COVID-19, these comorbidities comprised 23.7 and 30% (for hypertension) and 16.2% and 12% (for diabetes) of patients who develop more severe symptoms [11]. The increase in ACE2 activity in patients with hypertension has been demonstrated [31–33]. It is also possible that the administration of certain antihypertensive medications leads to an increase in ACE2 expression and/or activity [21,34]. In addition to hypertension, ACE2 levels have been shown to be elevated in animal models of both Type 1 and Type 2 diabetes [20,32,35,36]. Previous research has demonstrated that ACE2 expression (measured protein levels) and activity were higher in a db/db mouse model for diabetes and this same trial demonstrated that ACE activity is lower in these same mice, highlighting an important function of the in ACE/ACE2 ratio in health and disease [37].
ACE2 and COVID-19: using antihypertensive medications, pharmacogenetic considerations

Figure 1. Schematic representation of ACE2 within the renin–angiotensin–aldosterone pathway. Once infected, it is likely that augmentations of ACE2 and Ang(1–7) will be protective for the cardiac and pulmonary systems. In contrast Ang-II and the Type 1 receptor of Ang-II have been shown to be destructive to the cardiac system and result in pulmonary leakage and fibrosis.

In addition to hypertension and diabetes being common comorbidities for COVID-19, older individuals and males are more susceptible to the infection (and have demonstrated more severe cardiopulmonary complications from coronavirus), both of which are associated with differences in ACE2 levels. Early COVID-19 data, and data from SARS-CoV have shown a disproportionate influence on males, when compared with females [10]. ACE2 levels increase markedly in male sheep with age [38]. Specifically, ACE2 activity in sheep increases about 300% in males at one year while females had no change throughout development [38]. Age also influences ACE2 expression (mRNA and protein) in animal models and the sex differences in sheep do not emerge until post puberty [38]. Most studies demonstrate a decrease in ACE2 levels in older animals, and there may be a sex-dependent effect similar to animal models given the importance of estrogen on this pathway [39]. In additional work in rats, female rats had lower renal ACE2 activity compared with males and this difference was dependent on ovaries and ovarian hormones [40]. These data could explain why younger individuals seem to be able to transmit the virus, with lower levels of infection.

Using these comorbidity and demographic data available with early data on COVID-19 as a surrogate, using groups that have previously been shown to be associated with high ACE2 levels showing higher infection rates and severity of infection, it is possible that variation in ACE2 levels may alter the course of COVID-19. Given this, it is also possible that variants along the RAAS that are likely to influence ACE2 expression and/or activity may also influence the susceptibility to infection, severity of infection and potential complications, once infected.

Importance of ACE2 & Ang(1-7) augmentations post diagnosis with coronavirus respiratory infection

Interestingly, there is strong evidence that decreased ACE2 and Ang(1–7) levels are associated with poor prognosis in patients with respiratory dysfunction, including ALI and ARDS, similar to COVID-19 [3,8,41]. The ACE2/Ang(1–7) relationship with ACE/Ang-II is complex in that ACE2, and particularly Ang(1–7), have been shown to be primarily protective while ACE, and particularly Ang-II result in cardiopulmonary dysfunction (Figure 1). The primary cause of hospitalization in COVID-19 cases has been respiratory distress [10]. Also of interest, ACE2 and Ang(1–7) are cardioprotective, and a large number of patients that exhibit complications with COVID-19 demonstrate cardiac complications, including cardiomyopathy and heart failure [9]. It is possible that the protective mechanism of ACE2 and Ang(1–7) in the lungs and the heart are attenuated, with infection, and augmentation of this pathway may reduce the severity of the illness.
Lung

ACE2 has been shown to be localized to the lungs, as has one of the angiotensin receptors, AT1, but not AT2. There is a clear and important interaction of ACE2 and AT1 on lung protection in models of disease, including those caused by coronaviruses [7,8,42]. Genetic knock-out of AT1a receptor expression markedly improved lung function in mice with a genetic knockout of this receptor (Agtr1a<sup>−/−</sup> mice), confirming the function of Ang-II in lung health [5,43]. Additional work has shown that pharmacologic inhibition of the AT1 receptor attenuates the severity of acid-induced lung injury in ACE2 knockout mice and the loss of ACE2 expression in ALI leads to leaky pulmonary blood vessels through AT1a receptor stimulation [7]. ACE2 knockout mice developed more severe ALI in models that result in respiratory distress [41]. In models of acute ALI, acid-treated mice who have been genetically modified with a knockout for ACE2 have more lung elastase, when compared with wild-type mice, and this loss of ACE2 results in more pronounced deoxygenation, lung edema and increased inflammatory cell infiltration [7]. Additional work has demonstrated that ACE2 decreases fibroblast mitogenesis in pulmonary fibrosis [43]. Finally, injection of ACE2 seems to protect mice with ALI [7]. Previous research has demonstrated that the injection of SARS virus leads to an increase in Ang-II levels in lung tissue and exacerbates ALI in mice. Additionally, the viral spike from SARS seems to inhibit ACE2 that may result in increases levels of Ang-II. It is also possible that differences in ACE levels may influence pulmonary function and disease severity via an upstream (upstream of Ang-II) mechanism. An indirect influence of ACE on ACE2 is possible given that ACE levels will dictate the amount of Ang-II (for which ACE2 has a great affinity) and given the evidence that ACE-inhibition can increase ACE2 expression/activity in humans. There is one particular site of the ACE gene that has been studied in great detail, the presence (insertion, I) or absence (deletion, D) of a 287 base pair sequence of alu within intron 16 of the gene that encodes ACE. In fact, the D genotype of ACE is associated with ARDS susceptibility and outcome, where DD genotype was associated with ARDS [44], although this has not been demonstrated in all populations [45]. This same genotype of ACE is also associated with higher ACE activity, which would, theoretically, result in lower Ang-II levels. More recent data on COVID-19 has demonstrated important differences in race on infection rates and severity. Although this racial difference has been almost entirely attributed to the environment, there are known differences in minor allele frequency of several of the functional genes within the RAAS, which could also play a role [46–48]. It is also possible that other variants along the RAAS that could influence ACE2 levels (renin, angiotensinogen and the AT1a receptor) could alter endogenous ACE2 levels and be differentially affected by modulation using ACE-inhibitors or ARBs.

Heart

Previous work in coronaviruses has demonstrated that a high percentage of patients with complications have cardiac dysfunction, including cardiomyopathy and cardiac injury. A recently published trial demonstrated that a greater number of patients hospitalized with COVID-19 demonstrate cardiac injury [9]. It is possible that this cardiac dysfunction following the viral infection, is also due to a temporary drop in ACE2 levels, due to ACE2 destruction as a result of the infection. Previous evidence indicates that the infection can result in ACE2 destruction, reduction in membrane-bound ACE2 and that ACE2 has a protective role in the heart [13,49]. The disruption of ACE2 accelerates cardiac hypertrophy and shortens the transition period to heart failure in an Ang-II model of heart failure [29]. In addition, pharmacologic inhibition of ACE2 exacerbates cardiac hypertrophy and circulating Ang(1–7) levels in transgenic rats are associated with reduced cardiac hypertrophy and fibrosis following isoproterenol infusion [50,51]. The attenuation of Ang-II can help with cardiac remodeling in that both ACE inhibition and the administration of ARBs increase ACE2 activity and/or expression.

It is possible that patients who become infected with COVID-19 lose some of the pulmonary and cardiac protective mechanisms of ACE2 and Ang(1–7), due to viral binding and the resultant destruction of ACE2 following infection [49]. It is likely that those who have less severe disease/infection/death rates are in groups associated with higher ACE2 activity after infection, either due to genetic differences, demographic variables or medication utilization. In addition, it is possible that modification of some common antihypertensive medications including ACE-inhibitors and ARBs may augment ACE2 post infection and protect the cardiopulmonary system, although this remains a hypothesis and, clearly, medication adjustments should never be made without the consultation with a patient’s clinician [34].
Modifications of ACE2 with medications that alter the RAAS pathway

ACE2 has a 400–500 fold lower affinity for Ang-I than for Ang-II [43]. Ang-II is also a primary target for pharmacotherapy, along with ACE, which converts Ang-I into Ang-II. It is, therefore, plausible that alterations in Ang-II and ACE expression and/or activity because of more versus less functional genetic variants along the RAAS pathway could, theoretically alter ACE2 activity. Further, since the pathway is also dependent on renin, it is possible that reductions in renin levels, through renin inhibition, may alter ACE2 expression and/or activity. In fact, previous work has demonstrated that the administration of an ACE-inhibitor or an ARB causes an increase in Ang(1–7) levels [34]. In addition, both ACE-inhibition and ARB administration increase the activity, and expression, of ACE2, which may be differential based on variants of ACE and Ang-II that have previously been shown to alter enzyme and receptor function, respectively [34].

Given this complex interaction along a pathway that is commonly treated with antihypertensive medications, it is possible that pharmacotherapy can target this pathway in established ways to attenuate ACE2 levels and reduce the likelihood for infections from COVID-19 and that augmentation of this same pathway, increasing ACE2 and Ang(1–7) may be beneficial, post infection. Specifically, ACE-inhibition and ARB administration may protect against cardiopulmonary dysfunction following COVID-19 infection. These considerations may be particularly impactful when considering genetic variants along this same pathway that have previously demonstrated meaningful functionality in humans.

Conclusion

COVID-19 has rapid cause of dramatic morbidity and mortality worldwide. Many scientific teams are working toward long-term solutions that will attenuate/ablate COVID-19 but there may be potential to reduce transmission through reductions of ACE2 levels, and reduce cardiac and pulmonary complications, post infection, with the modulation of common medications along the RAAS pathway while more sweeping solutions are being developed. This may be of particular importance, from a pharmacogenetic perspective to reduce ACE2 levels in those genetically likely to have high ACE2 levels prior to infection and to increase ACE2 levels following infection with COVID-19 with genotypes associated with low ACE2 activity and/or function. Importantly, this remains a hypothesis based on data in animals and limited data in humans that deserves adequate clinical trials. Important clinical trial data would include well-designed mechanistic placebo-controlled trials of ACE2 activity and function before and following the administration of ACE-inhibitors and ARBs and large trials on the relationship between ACE2 and Ang(1–7) expression/activity on severity of infection in patients who have presented with a positive test for COVID-19. These clinical trials are needed to confirm these hypotheses and to demonstrate improvements in outcomes, while minimizing patient risk. The benefit of a trial on ACE2, COVID-19 and RAAS pharmacotherapies pharmacogenetics is that these medications are already FDA approved and most are in generic form which should shorten the time for these clinical trials while even more promising new therapies (including those that specifically target coronaviruses with a focus on membrane-bound versus circulating ACE2) are moving through phased clinical trials.

Financial & competing interested disclosure

EM Snyder is a cofounder and partial owner of Geneticure, Inc. which develops pharmacogenetic panels for chronic diseases. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.
Executive summary

Background
- COVID-19 utilizes the ACE2 pathway as a means of infection.
- Early data on COVID-19 suggests heterogeneity in the severity of symptoms during transmission and infection ranging from no symptoms to death.
- The source of this heterogeneity is likely multi-faceted and may have a genetic component.
- Demographic and clinical comorbidities associated with the severity of infection suggest that possible variants known to influence the renin–angiotensin–aldosterone (RAAS) pathway (those that influence ACE2) may contribute to the heterogenous infection response to COVID-19.

RAAS pathway & ACE2
- ACE2 is a relatively newly discovered enzyme in the RAAS pathway and is a homolog of ACE but appears to be counteractive in nature to the function and activities of ACE and the product of ACE, Ang-II.
- ACE2 hydrolyzes Ang-I to make Ang(1–9) and Ang-II to make Ang(1–7) which then binds to a g-protein coupled receptor MAS.
- ACE, ACE2, Ang-II and AT1 receptor levels are high in the lung, which seems to be the primary site of complications from the corona-type viruses.
- Functional variants of renin, angiotensinogen, ACE and the AT1 receptor have been studied in detail and common variants have been shown to alter plasma levels, activity and the response to pharmacotherapy.
- Several common and functional genotypes of ACE2 have been described.
- While it is likely that a portion of the differences in COVID-19 infection rates and severity are influenced by environment or traditional demographic variables known to influence ACE2 levels, the known heterogeneity of this infection may also have genetic associations.

Evidence that ACE2 may be associated with COVID-19 infection
- The early data from patients who have higher rates of infection, and who have had more severe COVID-19 suggest that there are two primary common comorbidities: hypertension and diabetes.
- There is an increase in ACE2 activity in patients with hypertension.
- In addition to hypertension, ACE2 expression and activity have been shown to be elevated in animal models of both Type 1 and Type 2 diabetes.
- Along with hypertension and diabetes being common comorbidities for COVID-19, older individuals and males are more susceptible to the infection (and have demonstrated more severe cardiopulmonary complications from coronavirus), both of which are associated with differences in ACE2 expression and activity.
- Age influences ACE2 expression (mRNA and protein) in animal models and sex differences in sheep do not emerge until post puberty.

Importance of ACE2 and Ang(1–7) augmentations post diagnosis with coronavirus respiratory infection
- Interestingly, there is strong evidence that decreased ACE2 and Ang(1–7) levels are associated with poor prognosis in patients with respiratory dysfunction, including acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). The ACE2/Ang(1–7) relationship with ACE/Ang-II is complex in that ACE2, and particularly Ang(1–7), have been shown to be primarily protective of the heart and lungs while ACE, and particularly Ang-II result in cardiopulmonary dysfunction.
- Lungs
  - Genetic knock-out of AT1a receptor expression markedly improved lung function in Agtr1a−/− mice, confirming the function of Ang-II in lung health.
  - Additional work has shown that pharmacologic inhibition of the AT1 receptor attenuates the severity of acid-induced lung injury in ACE2 knockout mice and the loss of ACE2 expression in ALI leads to leaky pulmonary blood vessels through AT1a receptor stimulation.
  - ACE2 knockout mice developed more severe ALI in models that result in respiratory distress and animals that have more lung elastase, when compared with wild-type mice, and this loss of ACE2 results in more pronounced deoxygenation, lung edema and increased inflammatory cell infiltration.
- Heart
  - Previous work in coronaviruses has demonstrated that a high percentage of patients with complications have cardiac dysfunction, including cardiomyopathy and cardiac injury.
  - The disruption of ACE2 accelerates cardiac hypertrophy and shortens the transition period to heart failure in an Ang-II model of heart failure.
  - In addition, the pharmacologic inhibition of ACE2 exacerbates cardiac hypertrophy and circulating Ang(1–7) levels in transgenic rats are associated with reduced cardiac hypertrophy and fibrosis following isoproterenol infusion.
  - Therefore, it is possible that variants along the RAAS that impact ACE2 levels may impact the progression of COVID-19

Modifications of ACE2 with medications that alter the RAAS pathway
- Previous work has demonstrated that the administration of an ACE-inhibitor or an ARB causes an increase in Ang(1–7) levels, in some studies.
In addition, both ACE-inhibition and ARB administration increase the activity, and expression, of ACE2, which may be differential based on variants of ACE and Ang-II that have previously been shown to alter enzyme and receptor function, respectively.

It is, therefore, possible that ACE-inhibition and ARB usage could beneficially alter ACE2 activity/expression, post infection, particularly in groups that are genetically prone to lower ACE2 activity/expression.

Like hypertension, not all individuals will likely have the same levels of ACE2 modulation with pharmacotherapy.

References

1. Hamming I, Timens W, Bultjens ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 203(2), 631–637 (2004).

2. Ge XY, Li JL, Yang XL et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503(7477), 535–538 (2013).

3. Jia HP, Look DC, Shi L et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J. Virol. 79(23), 14614–14621 (2005).

4. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronaviruses. J. Virol. 94(7), (2020).

5. Ferreira AJ, Murca TM, Fraga-Silva RA, Castro CH, Raizada MK, Santos RA. New cardiovascular and pulmonary therapeutic strategies based on the Angiotensin-converting enzyme 2/angiotensin–(1–7)/MAS receptor axis. Int. J. Hypertens. 2012, 147825 (2012).

6. Tikellis C, Thomas MC. Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. Int. J. Pept. 2012, 256294 (2012).

7. Imai Y, Kuba K, Rao S et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436(7047), 112–116 (2005).

8. Wu Y. Compensation of ACE2 function for possible clinical management of 2019-nCoV-induced acute lung injury. Viral. Sin. 35, 256–258 (2020).

9. Shi S, Qin M, Shen B et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. doi:10.1001/jamacardio.2020.0950 (2020) (Epub ahead of print).

10. Yang X, Yu Y, Xu J et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 8(5), 475–481 (2020).

11. Zhang JJ, Dong X, Cao YY et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy doi:10.1111/all.14238 (2020) (Epub ahead of print).

12. Thatcher SE, Gupte M, Hatch N, Cassis LA. Deficiency of ACE2 in bone-marrow-derived cells increases expression of TNF-alpha in adipose stromal cells and augments glucose intolerance in obese C57BL/6 mice. Int. J. Hypertens. 2012, 762094 (2012).

13. Ferreira AJ, Shenoy V, Qi Y et al. Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinase. Exp. Physiol. 96(3), 287–294 (2011).

14. Vangjeli C, Clarke N, Quinn U et al. Confirmation that the renin gene distal enhancer polymorphism REN-5312C/T is associated with increased blood pressure. Circ Cardiovasc. Genet. 3(1), 53–59 (2010).

15. Ajala AR, Almeida SS, Rangel M et al. Association of ACE gene insertion/deletion polymorphism with birth weight, blood pressure levels, and ACE activity in healthy children. Am. J. Hypertens. 25(7), 827–832 (2012).

16. Julve R, Chaves FJ, Rovira E et al. Polymorphism insertion/deletion of the ACE gene and ambulatory blood pressure circadian variability in essential hypertension. Blood Press Monit. 6(1), 27–32 (2001).

17. Tang W, Devereux RB, Rao DC et al. Associations between angiotensinogen gene variants and left ventricular mass and function in the HyperGEN study. Am. Heart J. 143(5), 854–860 (2002).

18. Yu H, Lin S, Liu G, Zhang Y, Deng C, Ma W. T1198C polymorphism of the angiotensinogen gene and antihypertensive response to angiotensin-converting enzyme inhibitors. Hypertens Res. 28(12), 981–986 (2005).

19. Cao Y, Li L, Feng Z et al. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov. 6, 11 (2020).

20. Cherney DZ, Xiao F, Zimpelmann J et al. Urinary ACE2 in healthy adults and patients with uncomplicated Type 1 diabetes. Can. J. Physiol. Pharmacol. 92(8), 703–706 (2014).

21. Bai F, Pang XF, Zhang LH et al. Angiotensin II AT1 receptor alters ACE2 activity, eNOS expression and CD44–hyaluronan interaction in rats with hypertension and myocardial fibrosis. Life Sci. 153, 141–152 (2016).

22. Jeunemaitre X. Genetics of the human renin angiotensin system. J. Mol. Med. (Berl.) 86(6), 637–641 (2008).

23. Goracy I, Dawid G, Loniewska B, Goracy J, Ciechanowicz A. Genetics of the renin-angiotensin system with respect to cardiac and blood pressure phenotypes in healthy newborn infants. J. Renin Angiotensin. Aldosterone Syst. 14(4), 357–347 (2015).
24. Li W, Greenough TC, Moore MJ et al. Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2. J. Virol. 78(20), 11429–11433 (2004).
25. Li W, Zhang C, Sai J et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 24(8), 1634–1643 (2005).
26. Bernardi S, Burns WC, Toffoli B et al. Angiotensin-converting enzyme 2 regulates renal atrial natriuretic peptide through angiotensin (1–7). Clin. Sci. (Lond.) 123(1), 29–37 (2012).
27. Ferreira AJ, Santos RA, Raizada MK. Angiotensin (1–7)/angiotensin-converting enzyme 2/mas receptor axis and related mechanisms. Int. J. Hypertens. 2012, 690785 (2012).
28. Baginski L, Tachon G, Felson F, Patton JS, Bakowsky U, Ehrhardt C. Reverse transcription polymerase chain reaction (RT-PCR) analysis of proteolytic enzymes in cultures of human respiratory epithelial cells. J. Aerosol Med. Pulm. Drug Deliv. 24(2), 89–101 (2011).
29. Yamamoto K, Ohishi M, Katsuya T et al. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 47(4), 718–726 (2006).
30. Lu N, Yang Y, Wang Y et al. ACE2 gene polymorphism and essential hypertension: an updated meta-analysis involving 11,051 subjects. Mol. Biol. Rep. 39(6), 6581–6589 (2012).
31. Tikellis C, Cooper ME, Bialkowski K et al. Developmental expression of ACE2 in the SHR kidney: a role in hypertension? Kidney Int. 70(1), 34–41 (2006).
32. Warner FJ, Guy JL, Lambert DW, Hooper NM, Turner AJ. Angiotensin converting enzyme-2 (ACE2) and its possible roles in hypertension, diabetes and cardiac function. Lett. Pept. Sci. 10(5), 377–385 (2003).
33. Yamaleyeva LM, Gilliam-Davis S, Almeida I, Brosnihan KB, Lindsey SH, Chappell MC. Differential regulation of circulating and renal ACE2 and ACE in hypertensive mRen2. Lewis rats with early-onset diabetes. Am. J. Physiol. Renal Physiol. 302(11), F1374–F1384 (2012).
34. Furuhashi M, Moniwa N, Mita T et al. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Am. J. Hypertens. 28(1), 15–21 (2015).
35. Soro-Paavonen A, Gordin D, Forblom C et al. Circulating ACE2 activity is increased in patients with Type 1 diabetes and vascular complications. J. Hypertens. 30(2), 375–383 (2012).
36. Bindom SM, Lazartigues E. The sweeter side of ACE2: physiological evidence for a role in diabetes. Mol. Cell. Endocrinol. 302(2), 193–202 (2009).
37. Wysocki J, Ye M, Soler MJ et al. ACE and ACE2 activity in diabetic mice. Diabetes 55(7), 2132–2139 (2006).
38. Chen K, Bi J, Su Y, Chappell MC, Rose JC. Sex-specific changes in renal angiotensin-converting enzyme and angiotensin-converting enzyme 2 gene expression and enzyme activity at birth and over the first year of life. Reprod. Sci. 23(2), 200–210 (2016).
39. Bukowska A, Spiller L, Wolke C et al. Protective regulation of the ACE2/ACE gene expression by estrogen in human atrial tissue from elderly men. Exp. Biol. Med. (Maywood) 242(14), 1412–1423 (2017).
40. Liu J, Ji H, Zheng W et al. Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are 17beta-oestradiol-dependent and sex chromosome-independent. Biol. Sex Differ. 1(1), 6 (2010).
41. Nagase T, Uozumi N, Ishii S et al. Acute lung injury by sepsis and acid aspiration: a key role for cytosolic phospholipase A2. Nat. Immunol. 1(1), 42–46 (2000).
42. Kuba K, Imai Y, Rao S et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 11(8), 875–879 (2005).
43. Meng Y, Li T, Zhou GS et al. The angiotensin-converting enzyme 2/angiotensin(1–7)/Mas axis protects against lung fibroblast migration and lung fibrosis by inhibiting the NOX4-derived ROS-mediated RhoA/Rho kinase pathway. Antioxid. Redox. Signal. 22(3), 241–258 (2015).
44. Marshall RP, Webb S, Bellingan GJ et al. Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 166(5), 646–650 (2002).
45. Chan KC, Tang NL, Hui DS et al. Absence of association between angiotensin converting enzyme polymorphism and development of adult respiratory distress syndrome in patients with severe acute respiratory syndrome: a case control study. BMC Infect. Dis. 5, 26 (2005).
46. Lehmann DJ, Cortina-Borja M, Warden DR et al. Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer’s disease. Am. J. Epidemiol. 162(4), 305–317 (2005).
47. Panza F, Capurso C, D’Onofro A et al. Differences in allele frequencies of ACE 1/D polymorphism between Northern and Southern Europe at different ages. Atherosclerosis 193(2), 455–457 (2007).
48. Panza F, Solfrizzi V, D’Onofro A et al. Angiotensin I converting enzyme (ACE) gene polymorphism in centenarians: different allele frequencies between the North and South of Europe. Exp. Gerontol. 38(9), 1015–1020 (2003).
49. Wang S, Guo F, Liu K et al. Endocytosis of the receptor-binding domain of SARS-CoV spike protein together with virus receptor ACE2. Virus Res. 136(1–2), 8–15 (2008).
50. Santos RA, Ferreira AJ, Nadu AP et al. Expression of an angiotensin-(1–7)-producing fusion protein produces cardioprotective effects in rats. Physiol. Genomics 17(3), 292–299 (2004).
51. Nadu AP, Ferreira AJ, Reudelhuber TL, Bader M, Santos RA. Reduced isoproterenol-induced renin-angiotensin changes and extracellular matrix deposition in hearts of TGR(A1–7)3292 rats. *J. Am. Soc. Hypertens.* 2(5), 341–348 (2008).